Switzerland-based CeQur has commenced a clinical study with the PAQ insulin delivery device for people with Type 2 diabetes.

The study is designed to demonstrate that Type 2 diabetes patients can successfully use PaQ to deliver their daily insulin.

CeQur founder and CEO, Jim Peterson, said the trial is a vital step in demonstrating that PaQ can be an effective option for the many people with Type 2 diabetes who struggle with the challenges of multiple daily insulin injections.

"The wearable device provides three days of consistent, basal insulin delivery, along with on-demand bolus insulin."

The wearable device, which comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor, provides three days of consistent, basal insulin delivery along with on-demand bolus insulin.

Glycemic control, patient satisfaction and safety are the endpoints of the study.

University Hospital Graz, Austria, endocrinology and metabolism division head, who is conducting the study, Thomas Pieber said: "There is a tremendous need for technologies, such as PaQ, that make insulin administration more comfortable, simple and convenient for patients, so that they are able to maintain better control of their disease and, therefore, their health."

"PaQ was thoughtfully designed to address many of the clinical and lifestyle issues that prevent patients from receiving their insulin as needed. We are excited to launch this study to demonstrate very specifically how the PaQ performs for these patients," Pieber added.

CeQur develops and commercialises advanced insulin delivery devices that make it easier for people living with Type 2 diabetes to adhere to therapy and stay in control of their disease.